Linnaeus Therapeutics
Michael Poisel is an experienced executive with a significant background in venture management and board leadership. Currently serving as the Executive Director of PCI Ventures at the University of Pennsylvania since January 2009, Michael focuses on accelerating the commercialization of Penn technology through entrepreneurial spinouts. Michael holds various board positions, including roles at Linnaeus Therapeutics, Exyn Technologies, and Ed Leadership Sims, where leadership aims to improve student achievement through innovative simulations. Previously, Michael has been involved with PhylloPharma as CEO and participated in the YTILI Fellowship at the U.S. Department of State. Michael's career also includes positions at Greater Philadelphia Alliance for Capital & Technologies, NewSpring, Apax Partners, and GE Equity. Educational credentials include an MBA and MSSE from The Wharton School and a BSME from Rose-Hulman Institute of Technology.
This person is not in the org chart
This person is not in any teams
Linnaeus Therapeutics
Linnaeus Therapeutics, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors.